Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company, announced that CFO Brandi Roberts will present at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 4:30 PM ET. The presentation will focus on the company's work in developing transformative medicines for neurological diseases, including candidates LP352 and LP659, which target specific G protein-coupled receptors. A live webcast will be available on Longboard's website, allowing for access to the presentation for at least 30 days afterward.

Longboard Pharmaceuticals aims to advance its pipeline, with LP352 targeting seizures linked to developmental and epileptic encephalopathies and LP659 aimed at multiple neurological conditions. The company emphasizes its commitment to innovation and the potential benefits of its therapies.

LA JOLLA, Calif.--(BUSINESS WIRE)-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard’s Chief Financial Officer, will present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023, at 4:30pm ET.

To access a webcast of the presentation, please visit the “Events & Presentations” page within the Investors Relations section of Longboard’s website at https://www.longboardpharma.com/. The presentation will be webcast live and archived on the website for at least 30 days following the event.

ABOUT LONGBOARD PHARMACEUTICALS

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of multiple neurological diseases.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard’s participation in the upcoming conferences, Longboard’s clinical and preclinical programs, ability to develop and deliver medicines, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005881/en/

CORPORATE CONTACT:

Megan E. Knight

Head of Investor Relations

IR@longboardpharma.com

858.789.9283

Source: Longboard Pharmaceuticals, Inc.

FAQ

When is Longboard Pharmaceuticals presenting at the Needham Virtual Healthcare Conference?

Longboard Pharmaceuticals will present on April 18, 2023, at 4:30 PM ET.

Who is presenting for Longboard Pharmaceuticals at the conference?

CFO Brandi Roberts will present on behalf of Longboard Pharmaceuticals.

How can I access the webcast of Longboard Pharmaceuticals' presentation?

The webcast can be accessed on the 'Events & Presentations' page of Longboard Pharmaceuticals' website.

What is Longboard Pharmaceuticals focusing on in their presentation?

The presentation will highlight Longboard's development of novel treatments for neurological diseases.

What are the main product candidates being discussed by Longboard Pharmaceuticals?

Longboard will discuss LP352 and LP659, targeting specific neurological conditions.